A Phase 1, Multi-center, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal function.

Start Date05 Mar 2024

Sponsor / Collaborator

Madrigal Pharmaceuticals, Inc.

EUCTR2022-002279-13-DE / Unknown statusPhase 3

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

Start Date21 Aug 2023

Sponsor / Collaborator

Madrigal Pharmaceuticals, Inc.

NCT05500222 / RecruitingPhase 3

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

Start Date26 Aug 2022

Sponsor / Collaborator

Madrigal Pharmaceuticals, Inc.

100 Clinical Results associated with Resmetirom

100 Translational Medicine associated with Resmetirom

100 Patents (Medical) associated with Resmetirom

Literatures (Medical) associated with Resmetirom

01 Jan 2024·Nature reviews. Gastroenterology & hepatology

Resmetirom safe for nonalcoholic fatty liver disease

Article

Author: Ray, Katrina

01 Jan 2024·Alimentary pharmacology & therapeutics

Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis

Author: Targher, Giovanni

LINKED CONTENT:

This article is linked to Harrison et al paper. To view this article, visit https://doi-org.libproxy1.nus.edu.sg/10.1111/apt.17734

01 Jan 2024·Alimentary pharmacology & therapeutics

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Article

Author: Bansal, Meena ; Anstee, Quentin M ; Harrison, Stephen A ; Schneider, David ; Younossi, Zobair M ; Noureddin, Mazen ; Taub, Rebecca ; Sanyal, Arun J ; Schattenberg, Jörn M ; Loomba, Rohit ; Ratziu, Vlad ; Kowdley, Kris V ; Bashir, Mustafa R ; Bedossa, Pierre

Summary:

Background:

Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo.

Aims:

To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]).

Methods:

MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes.

Conclusion:

The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).

189

News (Medical) associated with Resmetirom

17 Jun 2024

·www.globenewswire.com

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). The guidelines were developed as a joint effort by the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO), and provide healthcare providers an update on prevention, screening, diagnosis, follow-up and treatment for MASLD. The new guidelines were presented during the EASL congress 2024, and were released in the Journal of Hepatology2. “The inclusion of NIS2+® in the EASL-EASD-EASO clinical guidelines is a major scientific recognition based on solid evidence that NIS2+® could play an important role in identifying patients that may benefit from emerging treatments for MASH,” commented Dean Hum, Chief Scientific Officer at GENFIT. “Additionally, GENFIT’s diagnostic technology featured as a monitoring treatment response in a Phase 2 study on tirzepatide’s safety and efficacy for MASH, and was recently presented during the Late Breaking session at EASL and jointly published in the New England Journal of Medicine3,” he added. In the new guidelines, NIS2+® is included for the first time as a non-invasive tool to detect at-risk MASH, and is the only blood-based panel mentioned for this condition. With the recent U.S Food and Drug Administration approval of resmetirom in the US, and given that liver biopsy will be used sparingly in routine clinical practice due to its invasiveness and procedure-related limitations, alternative non-invasive panels with high predictive value validated for the detection of at-risk MASH such as NIS2+®, could play an important role in selecting individuals able to benefit from pharmacotherapy. The new Clinical Practice Guidelines on the management of MASLD can be found at: https://www.journal-of-hepatology.eu/article/S0168-8278(24)00329-5/fulltext ABOUT MASH MASH is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with an increased risk of cardiovascular disease along with long-term risk for progression to cirrhosis, leading to liver insufficiency and potential progression to liver cancer. MASH is a serious disease that often carries no symptoms in its early stages, but if left untreated can result in cirrhosis, cancer, and the need for liver transplant. The prevalence of MASH is rapidly increasing as a result of the growing obesity and diabetes epidemics and is believed to affect as much as 12 percent of people in the U.S. and six percent worldwide. ABOUT NIS2+® NIS2+® is a blood-based diagnostic technology specifically designed to detect at-risk MASH among patients with metabolic risk factors based on an independent 2-biomarker panel. It is an optimization of the NIS4® technology and was developed and validated by GENFIT as a robust technology across characteristics of interest such as type-2 diabetes, age and sex, allowing large-scale implementation in clinical practice. GENFIT continues to explore the possibility of obtaining regulatory approval and CE Certificates of Conformity, for the widespread use of an IVD test powered by NIS2+® technology in both the United States and Europe. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the FDA’s accelerated approval of Iqirvo® (elafibranor4) for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about the potential for NIS2+® to play an important role in identifying patients that may benefit from emerging treatments for MASH. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | Investors Tel: +33 3 2016 4000 | investors@genfit.com GENFIT | Media Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 Metabolic dysfunction-associated steatohepatitis2 DOI: https://doi-org.libproxy1.nus.edu.sg/10.1016/j.jhep.2024.04.0313 DOI: https://doi-org.libproxy1.nus.edu.sg/10.1056/NEJMoa2401943 4 Elafibranor will be marketed and commercialized by Ipsen under the trademark Iqirvo and may be prescribed immediately in the U.S. for eligible patients. Attachment GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Phase 2

13 Jun 2024

·www.globenewswire.com

From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) -- Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer. Fatty liver disease is now estimated to affect 1 in 3 adults worldwide, and its prevalence is increasing. Fatty liver disease during childhood, once unheard of, is also on the rise. Early detection and timely intervention, whether through lifestyle changes or medical treatments, are essential in stopping and even reversing the progression of the disease. “Act Now, Screen Today'' emphasizes that liver health is achievable, but action must begin immediately. Across the globe, partners are driving awareness and educational efforts and ensuring broader access to essential screenings and care. Global Fatty Liver Day, observed annually on the second Thursday of June, is a rallying cry for collective action to address the growing prevalence of fatty liver disease, the most common liver disease worldwide. “Act Now, Screen Today” reminds everyone that liver health is within reach. Here are specific actions you can take today: Take advantage of liver health screening events happening globally to get assessed for fatty liver disease or schedule a check-up with your doctor, especially if you are managing closely associated metabolic conditions like obesity or diabetesIncrease physical activity, as maintaining an active lifestyle can improve liver healthLearn about fatty liver disease and its risk factors to take proactive steps towards prevention and management yourself or learn more about the latest research and guidelines for your patients. With a robust pipeline of pharmaceutical treatments that address diverse mechanisms of action in progress, it is important to identify individuals’ position within the progression of fatty liver disease so that they are poised to receive the most appropriate care possible. Notably, pharmaceutical treatments are available (for certain groups with advanced disease) in two countries, the United States (resmetirom) and India (saroglitazar). “As a community, we stand at a critical time for the broader global health system to act now to support patients,” shares Donna R. Cryer, JD, Founder and CEO of GLI. “As pharmaceutical treatment options gain approval in different geographies, health payers and systems must listen to the call from global advocates and not place undue obstacles to care – whether that be required biopsy, ambiguous lifestyle requirements, or other hurdles – so that patients are able to access the care they require, no matter who or where they are.” Recognizing the importance of early detection, a diverse range of partners, including healthcare providers, patient advocacy groups, and community organizations, have joined forces to “Act Now, Screen Today” and launch screening events around the world. From Chile to Nigeria to the Netherlands, the Philippines, and beyond, these events aim to raise awareness, provide education, and offer screening services to individuals at risk of fatty liver disease or the providers who care for them. Global Fatty Liver Day activities are driving positive change at the grassroots level. “Global Fatty Liver Day is an urgent call-to-action to unite our global efforts to confront the scourge of fatty liver disease,” shares Cat Evans, Director of Program Operations at GLI. “We must act now. By working together, we have the power to create significant change in preventing and managing this pressing health issue through our collaborative efforts.” Although the challenge of fatty liver disease to the well-being of communities around the globe is great, the power of locally-rooted, collective efforts can turn the tide towards positive change by heightening awareness, equipping people and their healthcare providers with prevention and management tools, expanding understanding of the disease through research, and protecting future liver health through effective policies. About Global Liver Institute Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube, or visit www.globalliver.org. GLI is the host of Global Fatty Liver Day. Christine Maalouf Global Liver Institutecmaalouf@globalliver.org

12 Jun 2024

·www.biospace.com

Donanemab’s Promise, BIO Wrap and Mass Layoffs

The big news of this week so far was Monday’s FDA advisory committee for Eli Lilly’s Alzheimer’s drug donanemab, where the vote was unanimous in support of the anti-amyloid antibody. If approved, donanemab would be a direct competitor of Biogen and Eisai’s Leqembi, but analysts believe there’s plenty of room in the market for both, and even predict that donanemab’s potential approval could be beneficial for Leqembi in the long run by increasing investments in advocacy and infrastructure. The mood was decidedly different from last week’s FDA adcomm, which voted overwhelmingly against approving Lykos Therapeutics’ MDMA-assisted PTSD therapy. Interestingly, that vote came down less an hour before BioSpace Senior Editor Heather McKenzie hosted a panel at BIO where Dan Karlin, chief medical officer at MindMed, said he’d hoped the conversation would have been different. In other conference news, Eli Lilly and partners Boehringer Ingelheim and Zealand Pharma presented mid-stage results for their GLP-1 products in the MASH space at the Congress of the European Association for the Study of the Liver. These companies are eyeing a piece of the MASH market that Madrigal Pharmaceuticals first tapped into earlier this year when its therapy, Rezdiffra, was approved in March. Finally, CBRE published a report on challenges in finding R&D and manufacturing talent, and thousands of layoffs continue to hit the biopharma industry. According to our Layoff Tracker, there have been 14,000 positions cut this year, with BMS and Bayer being the unfortunate leaders, each with more than 1,500 layoffs underway. Still, analysts are optimistic that the second half of 2024 could be better, as an uptick in the financial markets might provide companies with money to spend on growing their workforces. Greg Slabodkin is the news editor at BioSpace. You can reach him at greg.slabodkin@biospace.com. Follow him on LinkedIn.  Heather McKenzie is a senior editor at BioSpace. You can reach her at heather.mckenzie@biospace.com. Follow her on LinkedIn. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn. > Listen on Spotify > Listen on Apple Podcasts > Listen on Amazon Music > Listen on iHeart

Drug ApprovalAccelerated Approval

100 Deals associated with Resmetirom

External Link

KEGG	Wiki	ATC	Drug Bank
D11602	-	-	DB12914

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fibrosis, Liver	US	Madrigal Pharmaceuticals, Inc.	14 Mar 2024
Nonalcoholic Steatohepatitis	US	Madrigal Pharmaceuticals, Inc.	14 Mar 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cirrhosis	Phase 3	US	Madrigal Pharmaceuticals, Inc.	26 Aug 2022
Liver Cirrhosis	Phase 3	PR	Madrigal Pharmaceuticals, Inc.	26 Aug 2022
Heterozygous familial hypercholesterolemia	Phase 2	DK	Madrigal Pharmaceuticals, Inc.	09 Feb 2017
Attention	Phase 1	US	Madrigal Pharmaceuticals, Inc.	05 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03900429 (FDA) Manual	Phase 3	Nonalcoholic Steatohepatitis \| Fibrosis, Liver	-	placebo	odswgnoskv(djiekztmte) = itllyiripb kvkhxogbkr (zqdolzuejl ) View more	Superior	14 Mar 2024
				REZDIFFRA (80 mg once daily)	odswgnoskv(djiekztmte) = umsufssonv kvkhxogbkr (zqdolzuejl ) View more
NCT03900429 (MAESTRO-NASH, Pubmed)	Phase 3	Nonalcoholic Steatohepatitis	966	Resmetirom 80 mg	fevkqmckuh(xcxaaowwrf) = hbsivafmhu gsyneogial (cqbmkyxqjd ) View more	Positive	08 Feb 2024
				Resmetirom 100 mg	fevkqmckuh(xcxaaowwrf) = tvzcvyhzmm gsyneogial (cqbmkyxqjd ) View more
MAESTRO-NASH (GlobeNewswire) Manual	Phase 3	Nonalcoholic Steatohepatitis	-	Resmetirom 100 mg	oaujthbxqj(vqbdjcbvux) = centpmmmvc queaeuxdxk (zlgvzozbpa ) View more	Positive	10 Nov 2023
NCT04197479 (MAESTRO-NAFLD1, Literature) Manual	Phase 3	Metabolic dysfunction-associated steatotic liver disease	972	resmetirom 100 mg	tlmaqbuyjx(gradgswvpb) = scohafrupd zzrcoffszx (eqjxwatkmo )	Positive	16 Oct 2023
				resmetirom 80 mg	tlmaqbuyjx(gradgswvpb) = yoeadvbwqj zzrcoffszx (eqjxwatkmo )
NCT04197479 (MAESTRO-NAFLD-1, EASL2023)	Phase 3	Metabolic dysfunction-associated steatotic liver disease	1,343	Resmetirom 100 mg	ttdvxaudoi(lacsbsnmlm) = flbahhisjm zwixtsecpp (hmtlocciyf ) View more	-	21 Jun 2023
				Resmetirom 80 mg	ttdvxaudoi(lacsbsnmlm) = okewjdqzah zwixtsecpp (hmtlocciyf ) View more
NCT03900429 (MAESTRO-NASH, EASL2023)	Phase 3	Nonalcoholic Steatohepatitis	966	Resmetirom 80 mg	udcbublunp(wusmybpjts) = wiklhedgbq lhuubjokkf (smoyfmzppp )	-	21 Jun 2023
				Resmetirom 100 mg	udcbublunp(wusmybpjts) = jalrdnygmw lhuubjokkf (smoyfmzppp )
NCT04197479 (MAESTRO-NAFLD-1, EASL2022)	Phase 3	Metabolic dysfunction-associated steatotic liver disease	-	Resmetirom 80 mg	jpblxixuwm(iqqmuaycii) = fczcmsftjr hgbflgiapa (ovaweqdrge ) View more	-	25 Jun 2022
				Resmetirom 100 mg	jpblxixuwm(iqqmuaycii) = gatbwpxiwm hgbflgiapa (ovaweqdrge ) View more
NCT04197479 (MAESTRO-NAFLD-1, EASL2022)	Phase 3	Metabolic dysfunction-associated steatotic liver disease	-	Resmetirom	abvwzofjbf(tclqalzwyh) = zmrfurtlws uardbivmrl (blewoyxrii ) View more	Positive	25 Jun 2022
				Placebo	abvwzofjbf(tclqalzwyh) = zvcfrbldze uardbivmrl (blewoyxrii ) View more
EASL2022	Phase 2	-	-	Resmetirom 80 mg	proerhuhnd(qaerrkyhvh) = gltcmnxlmh vxiwifceru (jmvzxfipbi )	-	23 Jun 2022
				Resmetirom 100 mg	proerhuhnd(qaerrkyhvh) = rilpoucehc vxiwifceru (jmvzxfipbi )
NASH_TAG2022	Not Applicable	Nonalcoholic Steatohepatitis	-	Resmetirom	ehcstxhrcv(yrglzevoda) = lpzylhmxak ivitkkpxkv (okcvswzmej, 1.1) View more	-	06 Jan 2022
				Placebo	ehcstxhrcv(yrglzevoda) = imbzbixlmx ivitkkpxkv (okcvswzmej, 1.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis